Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Rad LaboratoriesFRA:BUWA +2.02%75 EBITDA Margin % is 91.44% as of Jun. 2026, which is 336% above its 10-year median of 20.98. GuruFocus rates FRA:BUWA with a GF Score™ of 75/100 and a GF Value™ of €276.51 (Fairly Valued). The stock has 7 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks better than 78.8% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bio-Rad Laboratories EBITDA Margin % Related Terms
Bio-Rad Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BUWA vs GKOS, BRKR, GMED: EBITDA Margin % Comparison
For the Medical Devices subindustry, Bio-Rad Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories (FRA:BUWA) has a EBITDA Margin % of 91.44% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bio-Rad Laboratories and its competitors. This is 336% above median its historical median of 20.98. According to the industry distribution chart, Bio-Rad Laboratories ranks #173 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 21.2%.
Is Bio-Rad Laboratories' EBITDA Margin % too high?
Bio-Rad Laboratories' current EBITDA Margin % of 91.44% is 336% above median its 10-year median of 20.98. The Medical Devices & Instruments industry median EBITDA Margin % is 7.59. Bio-Rad Laboratories' value of 91.44% is 1104.7% above this industry median. Based on the distribution chart, Bio-Rad Laboratories ranks #173 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Rad Laboratories has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' EBITDA Margin % compare to GKOS and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #173 out of 816 companies for EBITDA Margin %. This places Bio-Rad Laboratories in the top 21% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.59. Bio-Rad Laboratories' value of 91.44% is 1104.7% above this benchmark. While the company's 10-year median is 20.98 vs. the industry median of 7.59, Bio-Rad Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.59, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Rad Laboratories's current EBITDA Margin % of 91.44% is 1104.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bio-Rad Laboratories and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Rad Laboratories's current EBITDA Margin % is 91.44%, which is 336% above median its own 10-year median of 20.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €276.51, compared to a current price of €303.00 — trading 9.6% above its estimated fair value. The current EBITDA Margin % is 91.44%, which is 336% above median its 10-year median of 20.98 and 1104.7% above the Medical Devices & Instruments industry median of 7.59. Bio-Rad Laboratories' overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current EBITDA Margin % is 91.44% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued.
The current stock price of €303.00 is trading 9.6% above its estimated GF Value™ of €276.51.
GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.
Key valuation signals for FRA:BUWA:
EBITDA Margin %: 91.44% (336% above median its 10-year median of 20.98)
GF Value™: €276.51 vs. price of €303.00 (9.6% above fair value)
Industry Position: 1104.7% above the Medical Devices & Instruments median (#173 of 816)
No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
75GF Score
Get the complete analysis for FRA:BUWA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BUWA has been successfully added to your 
